Effect of CREXONT® (IPX203, ER CD-LD) on Sleep in Patients with Parkinson’s Disease and Associated Sleep Disturbances (P3-17.015)

Okeanis Vaou; Simon Allard; Alan Morris; Ghazal Banisadr; Stanley Fisher; Robert Hauser

doi:10.1212/wnl.0000000000215165

June 9, 2026Neurology

Effect of CREXONT® (IPX203, ER CD-LD) on Sleep in Patients with Parkinson’s Disease and Associated Sleep Disturbances (P3-17.015)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effects of CREXONT® (IPX203) on sleep quality and nighttime motor states in patients with Parkinson’s disease.
Intervention with CREXONT® (IPX203) targeting sleep disturbances in Parkinson’s disease patients.
Assessment of both sleep quality and nighttime motor states during the trial.
Significant improvement in sleep quality was observed in patients using CREXONT®.
Reduction in nighttime motor disturbances recorded among participants receiving treatment.

Implication

Assesses sleep improvements in Parkinson’s disease patients, suggesting potential benefits of CREXONT®.

Abstract

To assess the potential benefits of CREXONT® (IPX203) on sleep quality and nighttime motor states in Parkinson’s disease (PD) patients with sleep disturbances.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vaou et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0566e5 https://doi.org/10.1212/wnl.0000000000215165

View at Publisher

Ask AI

Bookmark

Share

Effect of CREXONT® (IPX203, ER CD-LD) on Sleep in Patients with Parkinson’s Disease and Associated Sleep Disturbances (P3-17.015)

Key Points

Implication

Abstract

Discussion

Cite This Study

Effect of CREXONT® (IPX203, ER CD-LD) on Sleep in Patients with Parkinson’s Disease and Associated Sleep Disturbances (P3-17.015)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology